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ABSTRACT
Objectives Treatments for prostate cancer such 
as androgen deprivation therapy (ADT), surgery 
and radiation therapy can adversely affect sexual, 
urinary and bowel function. Preliminary research 
has demonstrated the efficacy of exercise to 
preserve sexual function in men with localised 
prostate cancer receiving ADT, though this has 
yet to be investigated in a metastatic setting. 
We examined the effects of a 12- week exercise 
programme comprising resistance, aerobic and 
flexibility training on sexual health and function 
in men with advanced prostate cancer.
Methods Patients with prostate cancer 
(70.0±8.4 year; body mass index 28.7±4.0 kg/
m2) with bone metastases (rib/thoracic spine, 
66.7%; lumbar spine, 43.9%; pelvis, 75.4%; 
femur, 40.4%; humerus, 24.6%; other sites, 
70.2%) were randomly assigned to supervised 
exercise 3 days/week (n=28) or usual care 
(n=29). Sexual health and function were 
assessed using the International Index of Erectile 
Function, the Expanded Prostate Cancer Index 
Composite and the EORTC- PR25 at baseline and 
12 weeks.
Results Patients attended 89% of planned 
sessions and there were no adverse events. 
After adjusting for baseline values, there was no 
significant difference between groups for any 
measure of sexual function and activity (p>0.05). 
Additionally, there was no significant difference 
between groups for urinary and bowel function 
assessed by the EORTC- PR25 (p>0.05).
Conclusions A short- term programme of 
supervised exercise does not appear to enhance 
indices of sexual health and function in men 
with advanced prostate cancer. Limitations of the 
intervention included the conservative modular 
exercise programme, which deliberately avoided 




Treatments for prostate cancer (PCa) 
such as androgen deprivation therapy 
(ADT), surgery and radiation therapy 
can adversely affect sexual, urinary and 
bowel function that may persist for years 
following cessation of treatment. The 
psychosexual burden on individuals with 
PCa is complex, impacted by the physical 
result of erectile dysfunction, in addition 
to the psychosocial impact of reduced 
sexual function, including shame, depres-
sion, loss of intimacy and so on.1 Prior 
research supports the use of exercise as 
an effective countermeasure to many of 
the treatment- related toxicities experi-
enced in men with PCa, though research 
in regards to exercise and sexual function 
in this area remains sparse. Nevertheless, 
higher levels of physical activity have been 
demonstrated to be significantly associ-
ated with better sexual functioning in men 
with PCa following radiotherapy.2 More-
over, our group has previously demon-
strated the ability of exercise to preserve 
sexual function in men with localised and 
locally advanced PCa receiving ADT.3 
However, the effects of exercise on sexual 
function in men with PCa in a metastatic 
setting have yet to be investigated.
We recently reported the findings from 
an exercise trial undertaken in patients 
with PCa with bone metastases in which 
self- reported improvements in physical 
function and objectively measured lower 
body strength resulted.4 Here we report 
the effects of the 3- month multimodal 
exercise programme on sexual activity in 
this same patient cohort.
METHODS
Participants and recruitment
As previously reported,4 103 patients 
with PCa with established bone metas-
tases were referred by their oncologist 
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or urologist to participate, with 57 patients enrolled 
in the trial. Individuals were excluded if they had any 
conditions that precluded safe exercise, or if patients 
were currently participating in structured exercise. 
The main reasons for exclusion were patients declined 
to participate (n=16), travel constraints/proximity to 
exercise site (n=9), other commitments (n=6), physi-
cian declined approval (n=5) and bone pain (n=5). 
Informed consent was obtained from all participants 
and the study was approved by the University Human 
Research Ethics Committee.
Study design and random assignment
This was a two- armed prospective randomised 
controlled trial.4 Assessments of body composition 
(dual- energy X- ray absorptiometry), physical function, 
psychosocial measures and blood biomarkers were 
obtained at baseline and after the 12- week interven-
tion. Following baseline assessments, patients were 
randomised in a ratio of 1:1 to either exercise or usual 
care using a computer- generated random assignment 
programme.
Exercise training programme
Details of the exercise programme have been described 
in detail elsewhere.4 Briefly, the programme was 
undertaken three times per week in an exercise clinic 
for ~60 min, supervised and comprised resistance, 
aerobic and flexibility exercise, using a modular 
approach with extent/location of bone metastases 
taken into account to avoid loading of the affected 
sites. Resistance exercise targeted major upper and 
lower body muscle groups involved three sets at 10–12 
repetition maximum intensity, using exercises (such as 
chest press, seated row, triceps extension, biceps curl, 
leg extension and leg curl) tailored to the individual in 
relation to metastases sites. Aerobic exercise involved 
20–30 min at 60%–85% estimated maximal heart rate 
using modes such as walking and cycling, while flex-
ibility training involved static stretching of the major 
muscle groups.
Outcomes
Outcome measures were erectile function using the 
International Index of Erectile Function (IIEF),5 
urinary, sexual, bowel and hormonal health- related 
quality of life domains using the Expanded Prostate 
Cancer Index Composite (EPIC)6 and disease- specific 
health- related quality of life using the EORTC- PR25.7 
Higher scores on the IIEF and EPIC questionnaires 
indicate higher levels of sexual, urinary and bowel 
function and sexual activity. For the EORTC- PR25, 
higher scores on the urinary, bowel and treatment 
symptom scales indicate higher symptomology/prob-
lems while a higher score for sexual activity indicates a 
higher level of functioning.
Statistical analyses
Data were analysed using IBM SPSS (IBM, Armonk, 
New York, USA). Normality of the distribution was 
determined using the Shapiro- Wilk test. Between- 
group differences in baseline characteristics were anal-
ysed using independent t- tests or the Mann- Whitney U 
test for continuous data, as appropriate, and χ2 test for 
categorical data. Analysis of covariance adjusted for 
baseline values was used to assess intervention effects 
on study outcomes. Data for the three outcome ques-
tionnaires (IEEF, EPIC and EORTC- PR25) were not 
normally distributed, consequently all outcome data 
were log transformed for analysis. Due to incomplete 
responses to some of the questionnaires, analysis was 
conducted using complete cases. Tests were two- tailed 
with significance set at an alpha level of p ≤0.05.
RESULTS
The men were aged 50–89 years with extensive bone 
metastatic lesions. There were no significant differ-
ences between groups at baseline for patient char-
acteristics (online supplemental table S1 in online 
supplemental file) and sexual activity and function 
(table 1), except for the EPIC, which was significantly 
higher (p=0.004) in the exercise group (table 1). No 
exercise- related adverse events or skeletal fractures 
were reported during the study and patients attended 
89% of planned sessions. After adjusting for baseline 
values, there were no significant differences for any 
measure of sexual function and activity following 
exercise (table 1). Additionally, there were no signifi-
cant differences for any measures of urinary and bowel 
function. When examining individual responsiveness 
to exercise, no patterns emerged for the outcome 
measures.
DISCUSSION
This is the first study reporting the effects of exercise 
on sexual activity and function in men with advanced 
PCa. The findings from our trial indicate that although 
patients with advanced PCa and bone metastases were 
able to undertake the exercise programme with no 
adverse events reported, it had no effect on indices 
of sexual function. A lack of effect of exercise in the 
current study may be due to the short- term nature of 
the exercise programme being only 3 months and the 
conservative modular exercise programme avoiding 
bone metastatic sites, providing an insufficient stim-
ulus to induce change in sexual function or activity. 
For many patients, this conservative exercise prescrip-
tion precluded compound resistance training exercises 
involving the large muscle groups. This likely limited 
neural, muscular, hormonal and systemic training 
adaptations potentially mechanistic in improving 
sexual function and activity. It is also possible that 
exercise alone may be insufficient to produce favour-
able changes in sexual function and activity in men 
with advanced disease compared with those with local-
ised disease.3
Currently, there is insufficient evidence regarding 
which interventions are effective in helping to manage 
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sexual dysfunction in PCa. Sexual function and sexual 
satisfaction though interrelated are distinct entities 
that are likely impacted by the complex interplay 
between natural ageing, treatment- related factors and 
psychosocial or interpersonal variables such as coping 
and intimacy. Emerging evidence suggests that psycho-
logical therapies may be effective in improving sexual 
health in PCa.8 It is likely that exercise may play a role 
in a larger, multimodal framework (including psycho-
sexual therapy, couples support, pharmacology etc.), 
rather than as a stand- alone intervention. Further, 
given the extensive benefits experienced by men with 
PCa undertaking exercise, including enhanced muscle 
mass, strength, physical function and quality of life, 
future research empirically testing an integrative 
model of PCa care may look to include exercise as a 
core component. In addition, the inclusion of targeted 
pelvic floor exercise as part of the overall programme 
might also be beneficial for this patient group, espe-
cially for those with extensive bone disease and unable 
to perform multiple resistance exercises and could be 
considered in future studies. In summary, although 
exercise was well tolerated and improved physical 
function, the results of our trial suggest that a short- 
term stand- alone exercise programme has no effect 
on indices of sexual health in men with advanced PCa 
with bone metastases.
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